Table 3 Subgroup analysis of the effect of corticosteroid prophylaxis of post-ERCP pancreatitis in clinical trials
From: Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis
| Â | Â | Â | Â | Â | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
Variable | Patients | Pooled OR (95% CI) | Z | p | χ2 | d.f. | p |
| Â | PEP | ||||||
Jadad score | Â | Â | Â | Â | Â | Â | Â |
   ≥ 3 | 2247 | 1.10 (0.85, 1.43) | 0.72 | 0.47 | 8.11 | 4 | 0.09 |
   ≤ 2 | 385 | 1.31 (0.70, 2.46) | 0.85 | 0.39 | 0.28 | 1 | 0.59 |
Setting | Â | Â | Â | Â | Â | Â | Â |
   Single centre | 1034 | 1.04 (0.66, 1.64) | 0.16 | 0.87 | 4.75 | 3 | 0.19 |
   Multicentre | 1598 | 1.17 (0.88, 1.56) | 1.07 | 0.29 | 3.84 | 2 | 0.15 |
| Â | Severe PEP | ||||||
Jadad score | Â | Â | Â | Â | Â | Â | Â |
   ≥ 3 | 1872 | 1.35 (0.47, 3.91) | 0.55 | 0.58 | 0.14 | 1 | 0.71 |
   ≤ 2 | 385 | 1.98 (0.62, 6.34) | 1.14 | 0.25 | 1.12 | 1 | 0.29 |
Setting | Â | Â | Â | Â | Â | Â | Â |
   Single centre | 914 | 1.99 (0.70, 5.67) | 1.28 | 0.20 | 1.12 | 2 | 0.57 |
   Multicentre | 1343 | 1.21 (0.37, 4.00) | 0.32 | 0.75 | NA | NA | NA |
| Â | Post-ERCP hyperamylasemia | ||||||
Jadad score | Â | Â | Â | Â | Â | Â | Â |
   ≥ 3 | 228 | 0.87 (0.52, 1.46) | 0.53 | 0.60 | NA | NA | NA |
   ≤ 2 | 184 | 1.24 (0.37, 4.22) | 0.35 | 0.73 | NA | NA | NA |
Setting | Â | Â | Â | Â | Â | Â | Â |
   Single centre | 184 | 1.24 (0.37, 4.22) | 0.35 | 0.73 | NA | NA | NA |
   Multicentre | 228 | 0.87 (0.52, 1.46) | 0.53 | 0.60 | NA | NA | NA |